Publication of Genetic Analysis’ 2021 Annual Report
(Oslo, April 21, 2022) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the Annual Report for the financial year of 2021. The Annual Report is available as an attached…
Notice of Annual General Meeting 2022
Oslo, Norway, April 21, 2022 – Notice is hereby served that the Annual General Meeting of Genetic Analysis AS (the “Company”) will be held on Thursday 28 April at 15:00…
Genetic Analysis strengthens its management team by hiring a Head of Operations
OSLO, NORWAY – 4 March 2022: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the Company has strengthened its management team by hiring Mr. Lars…
Year-End Report October – December 2021
(Oslo, 18 February 2022) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the year-end report for the period 1 October – December 31, 2021. The year-end report is available…
IMD – Institut für Medizinische Diagnostik launches the GA-map® Microbiome Test in Germany
OSLO, NORWAY/BERLIN, GERMANY – 15 February 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Institut für Medizinische Diagnostik (“IMD”), a part of the Medicover Group, announces today that IMD…
The Microbiome Test from Genetic Analysis AS launched on a new technology platform, GA-map® Dysbiosis Test kit now commercially available on the Luminex MAGPIX® system
OSLO, NORWAY – 1. February 2022: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has successfully completed the development and CE-marking of the GA-map®…
Genetic Analysis AS (GA) reports first commercial sales of the enhanced GA-map® Dysbiosis Test version 2
OSLO, NORWAY – 27th January 2022: Today, GA achieved another important milestone; first commercial sales of the new and enhanced version of the GA-map® Dysbiosis Test to the US market….
Genetic Analysis AS (GEAN): Mandatory notification of trade – Primary Insiders
OSLO, NORWAY – 13 January 2022: Genetic Analysis AS (“GA” or “the Company”) announce that members of the management have bought GEAN-shares. Ronny Hermansen, CEO in Genetic Analysis AS, has…
Genetic Analysis AS and Thalys Medical Technology Group enter Microbiome Laboratory Developed Test (LDT) agreement for the Chinese market
OSLO, NORWAY/SHANGHAI, CHINA – 13. January 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Thalys Medical Technology Group Corporation (“Thalys”) announces today that the parties have entered a Laboratory…
Genetic Analysis summarizes a successful year
OSLO, NORWAY – 21 December 2021: 2021 has been an eventful year for Genetic Analysis (“GA” or “the Company”), in which the Company made strong progress in a market that…
Interim report January – September 2021
(Oslo, 9 November 2021) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – September 30, 2021. The interim report is available…
Genetic Analysis awarded important US patent covering a companion diagnostic method for optimising IBS interventions
OSLO, NORWAY – 28 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces the award of an important patent (US20200400666) by the United States Patent and…
Genetic Analysis enters a Service Agreement with Eurofins ADME BIOANALYSES – The first CRO to offer the GA-map® Microbiome test
OSLO, NORWAY – 19 October 2021: Molecular diagnostics specialist, Genetic Analysis AS (GA) today announced a Service Agreement with Eurofins ADME BIOANALYSES, a Contract Research Organisation (CRO) providing diverse services…
Genetic Analysis receives important patent allowance in China
OSLO, NORWAY – 14 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has been awarded an important patent (CN107430644A) by the China…
Microbiome Dx Genetic Analysis raises USD 6.8 M in IPO
Microbiome Dx Genetic Analysis raises USD 6.8 M in IPO Closes up 50 % on first two days of trading as EU and US commercialisation drive of GA-map® platform begins…